Bladder Cancer Clinical Trial
Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612)
Summary
The purpose of this study was to evaluate the 2-Year Recurrence Rate of bladder cancer in randomized patients with tumor histology Ta, G1-G2 who received TransUrethral Resection of Bladder Tumor (TURBT) plus apaziquone versus those who received TURBT plus placebo.
Full Description
This was a Phase 3, multicenter, randomized, double-blind, placebo-controlled study. Within 14 days of Screening, eligible patients underwent a TURBT during Visit 1 (Day 0) following which they were immediately randomized in a 1:1 ratio to receive either placebo or 4 mg apaziquone, instilled in a volume of 40 mL into the bladder within 6 hours from the end of the TURBT procedure. After a 60-minute retention period, study drug was drained from the bladder.
A postoperative follow-up examination and review of the local pathology report were performed at Visit 2, which occurred 21 days (±10 days) after the TURBT (Week 3).
If the histology of the patient's tumor was confirmed as Ta, G1-G2 (ie, low grade according to World Health Organization [WHO]/International Society of Urologic Pathology [ISUP] classification), no further treatment was given and the patient was observed cystoscopically every 3 months through Year 2 for tumor recurrence (Visit 3 through Visit 10).
If the histology of the patient's tumor was other than Ta, G1 or G2 (low grade [WHO/ISUP classification]), further treatment was given in accordance with current treatment guidelines, and the patient was followed up cystoscopically every 3 months through Year 2 for tumor recurrence (Visit 3 through Visit 10).
All patients were to be followed for 2 years.
Eligibility Criteria
Inclusion Criteria:
All of the following questions must be answered "Yes" in order for the patient to participate in the study.
Has the patient given written informed consent?
Is the patient at least 18 years old?
Does the patient have transitional cell carcinoma of the bladder with clinically apparent tumor Ta, grade G1-G2?
If the patient is a female of childbearing potential, is she using an acceptable/effective method of contraception?
If the patient is a female of childbearing potential, has she had a negative serum pregnancy test within the past 14 days?
Is the patient willing and able to abide by the protocol?
Exclusion Criteria:
All of the following questions must be answered "No" in order for the patient to participate in the study.
Does the patient have more than 5 bladder tumors?
Does any single bladder tumor exceed 3.5 cm in diameter?
Does the patient have a single, primary bladder tumor <0.5 cm and has no previous diagnosis of bladder cancer?
Has the patient ever received EOquin(r)?
Does the patient have, or has the patient ever had, any bladder tumor known to be other than tumor Ta or grade G1 or G2 (low grade [WHO/ISUP classification])?
Does the patient have, or has the patient ever had any bladder tumor with histology other than transitional cell carcinoma?
Does the patient have, or has the patient ever had, carcinoma in situ (CIS)?
Does the patient have an active urinary tract infection?
Does the patient have a bleeding disorder or a screening platelet count < 100 x 109/L?
Does the patient have any unstable medical condition that would make it unsafe for him/her to undergo TURBT under general or spinal anesthesia?
Does the patient have screening hemoglobin < 10 mg/dL, a screening absolute neutrophil count < 1.5 x 109/L?
Does the patient have a known immunodeficiency disorder?
Has the patient received any investigational treatment within the past 30 days?
Is the patient breast feeding?
Does the patient have a history of interstitial cystitis?
Does the patient have a history of allergy to red color food dye?
Has the patient had transitional cell carcinoma of the bladder within the past 4 months?
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 76 Locations for this study
Anaheim California, 92801, United States
West Palm Beach Florida, 33407, United States
Marietta Georgia, 30060, United States
Roswell Georgia, 30076, United States
Hines Illinois, 60141, United States
Slidell Louisiana, 70458, United States
Baltimore Maryland, 21237, United States
Towson Maryland, 21204, United States
Royal Oak Michigan, 48073, United States
Hillsborough New Jersey, 08844, United States
Hillsborough New Jersey, 08844, United States
Bay Shore New York, 11706, United States
Manhasset New York, 11030, United States
New Hyde Park New York, 11040, United States
Greensboro North Carolina, 27403, United States
Winston-Salem North Carolina, 27103, United States
Bryn Mawr Pennsylvania, 19010, United States
Charleston South Carolina, 29425, United States
McAllen Texas, 78503, United States
Salt Lake City Utah, 84107, United States
Alexandria Virginia, 22304, United States
Calgary Alberta, T2V4R, Canada
North Vancouver British Columbia, V7L2P, Canada
Surrey British Columbia, V3V1N, Canada
Victoria British Columbia, V8T5G, Canada
Victoria British Columbia, V8V3N, Canada
Halifax Nova Scotia, B3H2Y, Canada
Barrie Ontario, L4M7G, Canada
Brantford Ontario, N3R4N, Canada
Burlington Ontario, L7N3V, Canada
Burlington Ontario, L7S1V, Canada
Kingston Ontario, K7L3J, Canada
Kitchener Ontario, N2N2B, Canada
London Ontario, N6A5W, Canada
Newmarket Ontario, L3X1W, Canada
North Bay Ontario, P1B7K, Canada
North York Ontario, M3B3S, Canada
Oakville Ontario, L6H3P, Canada
Orillia Ontario, L3V7V, Canada
Oshawa Ontario, L1H7K, Canada
Peterborough Ontario, K9J7B, Canada
Scarborough Ontario, M1P2T, Canada
Scarborough Ontario, M1S4V, Canada
Toronto Ontario, M4C5T, Canada
Toronto Ontario, M4N3M, Canada
Toronto Ontario, M5G2M, Canada
Toronto Ontario, M6A3B, Canada
Toronto Ontario, M6S4W, Canada
Laval Quebec, H7G2E, Canada
Montreal Quebec, H3G1A, Canada
Pointe Clare Quebec, H9R4S, Canada
Sherbrooke Quebec, J1H5N, Canada
Quebec , G1R3S, Canada
Białystok , 15-27, Poland
Bielsko-Biała , 43-31, Poland
Gdańsk , 80-40, Poland
Inowrocław , 88-10, Poland
Katowice , 40-07, Poland
Kielce , 25-73, Poland
Kościerzyna , 83-40, Poland
Kraków , 30-01, Poland
Lublin , 20-95, Poland
Pabianice , 95-20, Poland
Poznań , 61-28, Poland
Pruszków , 05-80, Poland
Rybnik , 44-20, Poland
Siedlce , 08-11, Poland
Szczecin , 70-11, Poland
Słupsk , 76-20, Poland
Warszawa , 00-41, Poland
Warszawa , 00-90, Poland
Warszawa , 02-00, Poland
Warszawa , 02-78, Poland
Warszawa , 04-74, Poland
Wrocław , 50-55, Poland
Wrocław , 51-12, Poland
Åódź , 90-54, Poland
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.